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Polymyxins are cationic lipopeptide antibiotics
active against many species of Gram-negative bac-
teria. We sequenced the gene cluster for polymyxin
biosynthesis from Paenibacillus polymyxa PKB1.
The 40.8 kb gene cluster comprises three nonriboso-
mal peptide synthetase-encoding genes and two
ABC transporter-like genes. Disruption of a peptide
synthetase gene abolished all antibiotic production,
whereas deletion of one or both transporter genes
only reduced antibiotic production. Computational
analysis of the peptide synthetase modules sug-
gested that the enzyme system produces variant
forms of polymyxin B (1 and 2), with D-2,4-diamino-
butyrate instead of L-2,4-diaminobutyrate in amino
acid position 3. Two antibacterial metabolites were
resolved by HPLC and identified by high-resolution
mass spectrometry and MS/MS sequencing as the
expected variants 3 and 4 of polymyxin B1 (1) and
B2 (2). Stereochemical analysis confirmed the pres-
ence of both D-2,4-diaminobutyrate and L-2,4-diami-
nobutyrate residues.
INTRODUCTION
Polymyxins are a family of cationic lipopeptide antibiotics pro-
duced by Gram-positive bacteria and active against many
Gram-negative bacteria. Although polymyxins are very potent
antibiotics, their clinical application is limited by their inherent
toxicity and the availability of other active and less toxic antibi-
otics. Polymyxin B (1 and 2) and polymyxin E (Figure 1) are the
two forms of polymyxins that have been used clinically, and
neurotoxicity and nephrotoxicity are major complications asso-
ciated with their use (Li et al., 2006). As a result, polymyxins
are typically administered to prevent, rather than to treat, infec-
tions, and are used in low concentrations in combination with
other antibiotics in topical, ophthalmic, and otic formulations
(Falagas and Kasiakou, 2006). Polymyxins have high affinity for
lipopolysaccharide, and recently have been embedded in hemo-
perfusion cartridges used to remove lipopolysaccharide from
blood and block initial stages of sepsis (Rachoin et al., 2010).
Polymyxin-conjugated polymers have also been proposed for
use as dressing materials to selectively remove Gram-negative1640 Chemistry & Biology 18, 1640–1648, December 23, 2011 ª2011bacteria, reduce the bacterial load in wounds, and speed healing
(Shepherd et al., 2011). These new applications for polymyxins
have resulted in a resurgence of interest in this family of com-
pounds in recent years. More importantly, the emergence of
multidrug-resistant Gram-negative bacteria including Pseu-
domonas aeruginosa, Acinetobacter spp., and Klebsiella pneu-
moniae, which are highly resistant to most antibiotics but
intrinsically sensitive to polymyxin B (1 and 2), has led to a reas-
sessment of these antibiotics (Gales et al., 2006).
Polymyxins consist of ten amino acids with a characteristic
polycationic heptapeptide ring and anN-terminal fatty acidmodi-
fication. The peptide ring is formed through cyclization of the
carboxyl group of L-threonine at position 10 (C terminus) with
the g-amino-containing side chain of the L-2,4-diaminobutyrate
(DAB) residue at position 4, and the a-amino group of this DAB
residue is attached to the lipotripeptide of the N terminus (Storm
et al., 1977). Several types of polymyxins have been identified,
withmolecular weights ranging from 1,129 to 1,218 Da (Govaerts
et al., 2002a, 2002b; Martin et al., 2003; Orwa et al., 2001; Parker
and Rathnum, 1975; Vogler and Studer, 1966). They differ in the
identity of the N-terminal lipid portion as well as the amino acids
at positions 3, 6, and 7. The fatty acid side chains of polymyxins
are predominantly isooctanoic ormethyloctanoic acids, although
other variants are also seen (Govaerts et al., 2002a).
Like many low molecular weight peptide antibiotics, poly-
myxins are produced by a nonribosomal peptide synthetase
(NRPS)mechanism (Martin et al., 2003;Marahiel, 1997; vonDo¨h-
ren et al., 1997). Although the chemical structures of many poly-
myxins have been known for years, studies on the molecular
mechanisms of their biosynthesis are still very limited. Only
recently, whole-genome sequences of two Paenibacillus poly-
myxa strains were made public (GenBank accession numbers
CP000154.1 and NC_014622.1), and one of them was reported
to contain a gene cluster encoding the NRPS genes for poly-
myxin biosynthesis and to produce polymyxin A (Choi et al.,
2009). Here we report the cloning, sequencing, and mutational
analysis of the gene cluster for polymyxin production in
P. polymyxa PKB1, and identify two unusual forms of polymyxin
that are produced by this organism.
RESULTS
Identifying the Gene Cluster
P. polymyxa PKB1 is an environmental isolate studied initially for
its ability to control fungal diseases of plants due to production of
the antifungal peptide fusaricidin (Beatty and Jensen, 2002).Elsevier Ltd All rights reserved
Figure 1. Structure of Polymyxins
(A) Structure of polymyxin B (1 and 2).
(B) Amino acid variations found in some naturally occurring polymyxins.
DAB, 2,4-diaminobutyrate.
Chemistry & Biology
Variants of Polymyxin BDuring characterization of the gene cluster for fusaricidin produc-
tion by P. polymyxa PKB1, two genomic libraries were prepared
(Li et al., 2007; Li and Jensen, 2008). The first contained frag-
ments of P. polymyxa PKB1 genomic DNA (gDNA) in the cosmid
vector, Supercos1, whereas the second library contained similar
gDNA fragments inserted into pSMART-FOS, a copy control
fosmid vector designed to prevent rearrangement of cloned
DNA fragments. A Supercos library clone, Col-8, that hybridized
with a threonine-specific adenylation domain probe was fully
sequenced and found to carry a gDNA fragment encoding part
of a putative polymyxin gene cluster (Figure 2A). We used the
sequence information from Col-8 and related cosmids to identify
fosmid clones containing overlapping DNA fragments, and then
analyzed them to obtain sequence information to complete the
polymyxin gene cluster. We screened the fosmid library (550
clones) with two nonradioactively labeled DNA probes, a
1.67 kb EcoRI fragment from near the 50 end of the polymyxin
gene cluster fragment in Col-8 and a 1.11 kb PCR product
amplified from a related cosmid, Col-15, representing the region
just beyond the 30 end of the polymyxin gene cluster fragment
in Col-8 (Figure 2A). A total of 16 fosmid clones was found to
hybridize with these two probes, and the hybridization results
were confirmed by PCR analysis using primers based on the
sequences of the probes. Restriction digestion pattern analysis
of these 16 fosmid clones identified 3 that were most likely to
contain the missing ends of the gene cluster, and subcloned
fragments from these were subjected to DNA sequencing. The
sequence information obtained from these three fosmid clones
provided42.7kbof contiguousP.polymyxaPKB1DNAsequence
encompassing the polymyxin gene cluster, which has been
deposited in GenBank under accession number JN660148.
Analyzing the Gene Cluster
The polymyxin gene cluster is 40.8 kb long and comprises five
open reading frames (ORF), pmxA, B, C, D, and E (Figure 2A).Chemistry & Biology 18, 1640–164pmxA, B, and E encode three subunits of an NRPS enzyme
system, and pmxC and D encode membrane permease compo-
nents of ABC-type transporter systems. The contiguous DNA
sequence obtained ended 8 bp upstream of the pmxA gene,
and no cosmid or fosmid clones extending further in this direc-
tion were available, so the identity of genes upstream of pmxA
could not be determined. Approximately 2 kb of DNA sequence
from beyond the end of pmxEwas obtained, and an ORF encod-
ing an apparent hypothetical protein was found in this region.
The protein shares very high homology with a hypothetical pro-
tein from Geobacillus sp. Y412MC10 (GenBank accession
number 003243619), as identified by BLAST analysis, but is
not apparently related to NRPS gene clusters and so it is not
considered to be a part of the polymyxin gene cluster.
Each NRPS-encoding ORF was translated into an amino acid
sequence, and the modular arrangement of the NRPS sys-
tem and the amino acid substrate incorporated by each module
was predicted using online software (PKS/NRPS Analysis; http://
nrps.igs.umaryland.edu/nrps). The amino acids specified by
each domain in the NRPSs are shown in Figure 2B. According
to this analysis, the order and arrangement of the NRPS-encod-
ing genes within the cluster are not colinear with the amino acids
in the polymyxin end product. pmxE was found to encode the
NRPS modules responsible for the incorporation of the first
five amino acids of polymyxin, pmxA encodes modules for the
next four amino acids, and pmxB encodes a single module
responsible for incorporating the last amino acid of polymyxin.
Because NRPS-encoding gene clusters are typically colinear
with their peptide product, this observation initially led us to
consider that the DNA fragment containing the cluster might
be rearranged. However, the same arrangement of ORFs was
recently reported for the polymyxin gene cluster in P. polymyxa
E681, which produces polymyxin A (Choi et al., 2009).
Mutational Analysis
To demonstrate conclusively that the gene cluster is responsible
for polymyxin production, the pmxE gene was disrupted by
deleting approximately 2.0 kb from the 50 end of the gene and
replacing it with an antibiotic resistance cassette (ApraRCmRoriT
cassette). This cassette includes apramycin and chloramphen-
icol resistance genes and an oriT region to support interspecies
conjugation, all flanked by FLP recombinase target sequences
(FRT). Mutagenesis was accomplished using a PCR-targeted
gene disruption protocol originally developed for mutagenesis
of the fusaricidin gene cluster in this species (Li et al.,
2007), and the validity of the mutants was confirmed by PCR
analysis. The resulting pmxE mutant and wild-type strains of
P. polymyxa PKB1 were grown in glucose starch calcium
carbonate (GSC) medium, and methanol extracts of culture
supernatants were assayed for bioactivity against Escherichia
coli DH5a by agar diffusion bioassay. Supernatant from the
wild-type strain gave a clear zone of inhibition against the indi-
cator organism, but no bioactivity was observed for the extract
of supernatant from the pmxE mutant (Figure 3A). This demon-
stration that the disruption of pmxE completely abolishes
the antimicrobial activity of P. polymyxa PKB1 against E. coli
strongly suggests that the gene cluster is involved in polymyxin
production. It also indicates that the polymyxin product is the
sole contributor to the antibiotic effect against E. coli.8, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1641
Figure 2. Gene Cluster for Polymyxin Biosynthesis
in P. polymyxa PKB1
(A) Gray arrows represent NRPS genes whereas black
arrows represent ABC transporter-like genes, and the
direction of the arrows indicates the direction of tran-
scription. Black bars, labeled probes 1 and 2, represent
the probes used to screen the fosmid library. The figure is
drawn to scale.
(B) Module and domain arrangement of the NRPSs for
polymyxin biosynthesis.
See also Figure S3 in support of this figure.
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Variants of Polymyxin BABC transporter genes are present in the middle of the poly-
myxin biosynthetic gene cluster of P. polymyxa PKB1 and were
also reported in that of P. polymyxa E681 (Choi et al., 2009),
but the role of these genes was not examined in the previous
study. To determine their role in polymyxin biosynthesis, three
deletion mutants were prepared by individually deleting pmxC
(DpmxC) or pmxD (DpmxD), and by deleting both pmxC and
pmxD together (DpmxC+D), again using the PCR-targeted
gene disruption protocol and replacing the deleted genes with
ApraRCmRoriT cassettes. The validity of the mutants was again
demonstrated by PCR analysis. The mutant and wild-type
strains were grown in GSC medium, and methanol extracts of
culture supernatants were assayed for antimicrobial activity
against E. coli DH5a by agar diffusion bioassay. Whereas the
wild-type strain produced metabolites active against E. coli
DH5a as described earlier, this bioactivity was reduced in both
the DpmxC and DpmxD mutants (Figure 3B). The bioactivity of
the DpmxC mutant was slightly less than that of the DpmxD
mutant, but the effects of the mutations were not additive
because the residual bioactivity of the DpmxC+D double mutant
was the same as that of the DpmxC single mutant.
In NRPS gene clusters, ORFs are often transcribed as very
large multicistronic transcripts, which leaves open the possibility
that the reduction of polymyxin production seen in the DpmxC
and DpmxD single mutants and in the DpmxC+D double mutant
might be due to polar effects of the mutations on expression of
the downstream gene, pmxE. To address this issue, a mutant
carrying an unmarked, in-frame deletion of pmxC and pmxD
(DpmxC+D-IF) was prepared. An FLP recombinase-catalyzed
procedure was used to remove the pmxC+D genes from the
wild-type strain, leaving in their place an 81 bp in-frame ‘‘scar’’1642 Chemistry & Biology 18, 1640–1648, December 23, 2011 ª2011 Elsevier Ltd All r(Gust et al., 2003). Once again, the identity of
the in-frame mutant was verified by PCR anal-
ysis. An agar diffusion bioassay of methanol
extracts of the culture supernatants of the
DpmxC+D and DpmxC+D-IF mutants indicated
that both types of mutants had their bioactivities
reduced to about the same extent as compared
to the wild-type (Figure 3B), thereby discounting
the possibility that the reduction in bioactivity
was due to polar effects.
During a previous study of fusaricidin biosyn-
thesis, the fusaricidin gene cluster was demon-
strated to lack any potential transporter genes,
leading to the hypothesis that a transporter
gene from some other NRPS gene cluster mightbe responsible for export of fusaricidin as well as its cognate
peptide products. Because both fusaricidin and polymyxin are
cationic lipopeptides, the transporters from the polymyxin
gene cluster seemed good candidates to fulfill this function.
The culture supernatants of DpmxC, DpmxD, and DpmxC+D
mutants, wild-type, and aDfusAmutant (with the NRPS for fusar-
icidin biosynthesis disrupted) available from a previous study
(Li et al., 2007) were bioassayed for antifungal activity from fusar-
icidin using Leptosphaeria maculans as indicator organism.
A pattern similar to that of polymyxin was observed. Antifungal
bioactivity due to fusaricidin was not abolished, but was mark-
edly reduced in DpmxC and DpmxD single mutants and in
the DpmxC+D double mutant (Figure 3B). Culture supernatant
from the DfusA mutant showed no bioactivity against
L. maculans. This suggests that transport of both polymyxin
and fusaricidin is mediated, at least in part, by the pmxC and
pmxD genes of the polymyxin gene cluster. Because the fusari-
cidin gene cluster is not linked to the polymyxin gene cluster, this
further supports our contention that the reduced bioactivity seen
in transporter gene mutants is not due to polar effects.
Amino Acid Composition of Polymyxin
Although several structural types of polymyxins have been
described, only one polymyxin gene cluster sequence, that of
P. polymyxa E681, has been reported to date (Choi et al.,
2009). It supports the production of polymyxin A, a rare form of
polymyxin previously described only once, in 1947 (Ainsworth
et al., 1947). In contrast, bioinformatic analysis of the NRPS
encoded by the polymyxin gene cluster in P. polymyxa PKB1
predicted an amino acid composition identical to that of poly-
myxin B (1 and 2), except that the presence of an epimerizationights reserved
Figure 3. Production of Bioactive Metabolites by Wild-Type and
Mutant Strains of P. polymyxa PKB1
(A) Agar diffusion bioassay of clarified methanol extracts (100 ml) of culture
supernatants from wild-type, DpmxC+D, and DpmxE strains.
(B) Bioactivity due to polymyxin and fusaricidin production by various mutant
strains.
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Variants of Polymyxin Bdomain in module 3 suggested that a D-DAB residue would be
found in this position instead of the L-DAB found in polymyxin
B (1 and 2) (Figure 2B). The overall sequence homology between
the polymyxin gene clusters of P. polymyxa PKB1 and E681 is
very high, about 92%at the nucleotide sequence level. However,
in those regions of the cluster corresponding to the adenylation
domains of modules 6 and 7, sequence homology dropped con-
siderably, consistent with the prediction that different amino
acids would be specified by those modules in polymyxin A
fromP. polymyxa E681, versus the polymyxin B (1 and 2) variants
of P. polymyxa PKB1. Polymyxin B (1 and 2) is one of the more
common forms of polymyxin discussed in the literature. In con-
trast, no polymyxin B (1 and 2) structural variant with D-DAB in
position 3 has ever been reported, and so we considered the
possibility that the epimerization domain in module 3 might be
cryptic and that the gene cluster from P. polymyxa PKB1 might
actually support production of authentic polymyxin B (1 and 2).
Analysis of the Bioactive Compounds
To characterize the compound responsible for the antibacterial
bioactivity of P. polymyxa PKB1, we analyzed culture superna-Chemistry & Biology 18, 1640–164tants from the wild-type and mutant strains by HPLC and
LC-MS. The metabolites in wild-type culture supernatant were
first concentrated by adsorption to a Sep-Pak C18 cartridge
and elution with methanol before separation by reverse-phase
HPLC analysis. A 100 ml sample equivalent to 2 ml of culture
supernatant was analyzed, and eluent fractions (1 ml) were
collected and assayed for bioactivity against E. coli DH5a by
agar diffusion bioassay. Two bioactive peaks were resolved in
the HPLC profile of the wild-type culture supernatant sample
(Figure 4A). Both peaks were missing from the DpmxE mutant
and reduced in size in the DpmxC+D deletion mutants
(Figure 4B).
LC-MS analysis of the wild-type culture supernatant concen-
trate showed that the two peaks contained ions with masses
consistent with polymyxin B1 (1) and B2 (2) (Figure 4; see Fig-
ure S1 available online). High-resolution MS confirmed the pro-
posed molecular formulas, and MS/MS analysis (Figure 4; Fig-
ure S1; Table S1) confirmed that the amino acid sequence is
the same as for polymyxin B (1 and 2). However, when we
analyzed a commercial polymyxin B (1 and 2) sample, which is
a mixture of polymyxin B1 (1) and B2 (2) predominantly, the
HPLC retention times for the bioactive peaks in a methanol
extract of P. polymyxa PKB1 wild-type culture supernatant did
not correspond to the peaks for authentic polymyxin B1 (1) and
B2 (2) (Figure 5). This observation indicated that the bioactive
compounds produced by P. polymyxa PKB1 are likely to be
novel forms of polymyxin B1 (1) and B2 (2) with a D-DAB residue
in position 3, as suggested by the bioinformatic analysis
and, therefore, that the epimerization domain in module 3 is
functional.
To confirm the stereochemistry of the amino acid residues in
the polymyxins produced by P. polymyxa PKB1, degradation,
derivatization, and chiral GC/MS analysis was carried out for
material from each of the two bioactive peaks after purification
by semipreparative HPLC (Figure 6; Figure S2). Each polymyxin
peptide was hydrolyzed to its constituent amino acids and deriv-
atized as the corresponding pentafluoropropanamide isopropyl
ester. The derivatized peptide hydrolysates were analyzed by
chiral GC/MS both individually and together with derivatized
amino acid standards (Ku¨sters et al., 1984). The two bioactive
peptides each contained the same constituent amino acids:
L-threonine, L-leucine, D-phenylalanine, L-DAB, and D-DAB.
The relative peak areas of the DAB residues indicated a ratio of
L:D DAB of 5:1, which again corresponds to the composition
predicted by bioinformatic analysis.
Polymyxin antibiotics are lipopeptides, and yet no genes are
found in the polymyxin gene cluster from P. polymyxa PKB1 to
account for the lipidation of the peptide moiety. The DNA
sequence available for the cluster extends just 8 bp upstream
of the pmxA start codon, leaving open the possibility that genes
associated with the activation or transfer of fatty acids might be
found in this region. However, no such genes are found adjacent
to the polymyxin clusters in either of the other P. polymyxa
strains for which sequence information is available, and so it
seems more likely that polymyxin synthesis resembles surfactin
synthesis, and relies upon lipidation functions encoded else-
where in the chromosome. In this regard, the N-terminal con-
densation domain of pmxE, which precedes the thiolation and
adenylation domains for the first amino acid, L-DAB, shows8, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1643
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Figure 4. HPLC and Mass Spectrometry Analysis
of Culture Supernatants of P. polymyxa PKB1
Wild-Type and Mutant Strains
(A) Methanol extract of wild-type culture supernatant was
separated by HPLC, and fractions were collected and
bioassayed to locate active peaks. Each active peak was
analyzed by LC-MS, and the mass spectra obtained are
shown (insets).
(B) HPLC profiles for methanol extracts of culture super-
natants from wild-type and DpmxE and DpmxC mutant
strains.
See also Figure S1 and Table S1 in support of this figure.
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Variants of Polymyxin Bsimilarity to so-called starter condensation domains that attach
lipids to amino acids in other lipopeptides, rather than catalyzing
the formation of a peptide bond between two amino acids. Two
alternative systems have been described for lipid attachment,
typified by the surfactin, plipstatin, lichenysin system in Bacillus
spp. and the ramoplanin, daptomycin system in actinomycetes.
The starter domain for polymyxin formation in P. polymyxa PKB1
clearly shows a closer relationship to the surfactin-type system
than to the actinomycete system (Figure 2B; Figure S3).1644 Chemistry & Biology 18, 1640–1648, December 23, 2011 ª2011 Elsevier Ltd All rDISCUSSION
The gene cluster responsible for the production
of polymyxin in P. polymyxaPKB1was identified
and subjected to DNA sequence analysis. The
cluster shows extensive similarity to the poly-
myxin gene cluster from P. polymyxa E681, the
only other polymyxin cluster reported to date,
but notable differences are also evident. Overall,
the sequences of the two clusters are highly
similar except for the first two modules of
pmxA, which correspond to amino acid residues
6 and 7 in the polymyxins, the amino acids that
differ between polymyxin A and polymyxin
B (1 and 2). P. polymyxa E681 produces only
one form of polymyxin, polymyxin A1, which is
consistent with the sequence of its gene cluster.We now show that P. polymyxa PKB1 produces two unusual
polymyxins, and we propose that these two new metabolites
are stereochemical variants 3 and 4 of polymyxin B1 (1) and
B2 (2). Both of these variant metabolites have the same amino
acid composition, and this composition is consistent with that
predicted by bioinformatic analysis of theNRPS-encoding genes
of the gene cluster. They differ from one another in the nature of
the lipid side chain, whichmass spectrometric analysis suggests
is isooctanoate in the case of peak 1 and methyloctanoate in theFigure 5. HPLC Analysis of Culture Super-
natant from Wild-Type P. polymyxa PKB1
in Comparison to Authentic Polymyxin B
Standard
Samples of methanol extracts of culture super-
natant alone, polymyxin B standard alone, and an
equal mixture of the two were subjected to HPLC
analysis. Fractions were collected and analyzed
for bioactivity. Bioactive peaks are marked with
an ‘‘3.’’
ights reserved
Figure 6. Chiral GC/MS Chromatogram
Showing the Constituent Amino Acids
of D-DAB3-Polymyxin B1 (3) after Acidic
Hydrolysis and Subsequent Derivatiza-
tion as Pentafluoropropanamide Isopropyl
Esters
The amino acids of the peptides are labeled on the
trace. See also Figure S2 in support of this figure.
Figure 7. Chemical Structure of D-DAB3-Polymyxin B1 (3) and
D-DAB3-Polymyxin B2 (4)
B1 when R = CH3 and B2 when R = H.
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Variants of Polymyxin Bcase of peak 2. We designate these variant forms D-DAB3-
polymyxin B1 (3) and D-DAB3-polymyxin B2 (4) (Figure 7) to indi-
cate that they differ from normal polymyxin B1 (1) and polymyxin
B2 (2) only in the stereochemistry of the DAB residue in position
3, which is L-DAB in normal polymyxin B (1 and 2) but D-DAB in
these new compounds. Because the biological properties of
peptide antibiotics can be markedly affected by the presence
of D-amino acids (Hong et al., 1999; Lee et al., 2004), these
new variants of polymyxin B (1 and 2) may have novel activity
or spectrum properties worth evaluation. In particular, the loca-
tion of the D-DAB3 residue as the first amino acid in the lipotri-
peptide side chain adjacent to the heptapeptide ring of the
polymyxins may make the structural consequences of the varia-
tion even more pronounced (Velkov et al., 2010).
Secondary metabolites are often produced as families of
compounds closely related in structure, and the particular array
ofmetabolites produced varies depending on the composition of
the growth medium and cultural conditions. This variability in the
nature of the end products is due to flexibility in the substrate
specificity of the enzymes involved, such that a single suite of
biosynthetic enzymes gives rise to all of the various structural
forms (Kajimura and Kaneda, 1997; Schimana et al., 2001). In
contrast, we now see that the polymyxin family of antibiotics
apparently arises, not from a single NRPS system with relaxed
substrate specificity, but rather from an array of closely related
NRPSs, each carrying a different complement of modules spec-
ifying the amino acids particular to its polymyxin product. Thus,
the collection of polymyxin NRPSs found in the various strains of
P. polymyxa that have been isolated over the years represents
a naturally occurring example of combinatorial biochemistry
driven by evolution rather than by in vitro manipulation. Examina-
tion of the junctions that have evolved naturally between
modules in these various forms may provide insights that can
inform the attempts of researchers seeking to create novel
peptide antibiotics artificially.
The polymyxin gene cluster from P. polymyxa E681 became
available upon analysis of the complete genome sequence forChemistry & Biology 18, 1640–1648, December 23, 2011 ªthis strain, and a second P. polymyxa
complete genome sequence, for strain
SC2, has recently become available. No
analysis of the polymyxin gene cluster
has yet been reported for the SC2 strain,
but evidence of some elements of a poly-
myxin gene cluster is present. However,
many of the polymyxin-producing genes
are listed as pseudogenes and appear
to be truncated or rearranged. Another
possibility is that this region of the ge-
nome sequence has not yet been fullyverified, and that an intact polymyxin gene cluster does exist in
the strain. The nature of theNRPS-encoding genes for polymyxin
biosynthesis makes it very difficult to assemble fragments of
DNA sequence correctly. NRPS modules, regardless of the
amino acids that they specify, show a considerable degree of
sequence similarity. The six DAB-specifying modules found in
the polymyxin NRPSs have long stretches of sequence that are
nearly 100% identical, and so assembling DNA sequence infor-
mation, as well as performing any experimental techniques that
rely upon hybridization of probes or primers to a DNA template
such as Southern hybridization and PCR, is exceptionally chal-
lenging. With this in mind, we examined the SC2 pmxA, B, and
E genes as identified in the genome sequence deposit using
the PKS/NRPS Analysis website (http://nrps.igs.umaryland.
edu/nrps), and were able to identify several modules, including
module 3 from the pmxA gene, which specifies that there would
be a D-DAB residue in this position if a polymyxin product is
produced by this strain.
It is striking that the first polymyxin gene cluster, that from
P. polymyxa E681, supported the production of polymyxin A,2011 Elsevier Ltd All rights reserved 1645
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Variants of Polymyxin Ba rare form of polymyxin containing a D-DAB residue in posi-
tion 3, and bioinformatic examination of the genome sequence
of P. polymyxa SC2 suggests that it may also produce a poly-
myxin containing a D-DAB residue in position 3. We now report
the polymyxin gene cluster of a third P. polymyxa strain, PKB1,
and, again, it specifies a polymyxin with D-DAB in position 3.
This stands in marked contrast to the literature, which would
suggest that these forms of polymyxins are rare. Production of
peptide metabolites is not a uniform property of all members
of this species, with production of various peptide products
reported for only certain strains of the species. Perhaps the
fact that all three of the polymyxin gene clusters examined to
date are from strains of P. polymyxa isolated and studied for their
potential as agents of biocontrol of plant fungal diseases is rele-
vant to this observation. All three strains are also producers of
fusaricidin, and this may mean that these strains are a closely
related subgroup of P. polymyxa strains, in evolutionary terms.
SIGNIFICANCE
The polymyxin gene cluster from Paenibacillus polymyxa
PKB1 has been sequenced and the two major polymyxin
products (3 and 4) produced by this strain have been identi-
fied as unusual forms of polymyxin B (1 and 2), with D-DAB
residues in place of L-DAB in amino acid position 3. The
substitution of L for D forms of amino acids in peptide anti-
biotics can markedly influence both the spectrum and de-
gree of bioactivity. Polymyxins are considered to be drugs
of last resort to combat infections by multidrug-resistant
Gram-negative bacteria, and so this report of variant forms
of polymyxins may be of therapeutic interest if the products
have altered bioactive properties or reduced toxicity. To
date, only one gene cluster for polymyxin biosynthesis has
been described in the literature. This work provides the
sequence of a second cluster and indicates that the different
forms of polymyxins arise from nonribosomal peptide syn-
thetases (NRPSs) that have evolved to contain modules
with different specificity codes, rather than arising from
a single flexible-substrate NRPS system. It also raises
interesting questions about the evolutionary relationships
between polymyxin-producing organisms, and provides
data potentially useful for making new forms of polymyxin
through site-directed mutation of NRPS gene sequences.
EXPERIMENTAL PROCEDURES
Bacterial Strains, Plasmids, and Culture Conditions
Bacterial strains and plasmid, cosmid, and fosmid vectors used in this study
are listed in Supplemental Experimental Procedures. E. coli strains were
routinely grown in Lennox broth (LB) at 37C for 16 hr on a shaker at
250 rpm or a tube roller. Antibiotics were added to the medium when appro-
priate at the following concentrations: 100 mg/ml ampicillin, 50 mg/ml apramy-
cin, 25 mg/ml chloramphenicol, and 50 mg/ml kanamycin. LB agar mediumwas
prepared by adding 15 g/l agar to the LB. E. cloni Replicator (Lucigen) strains
containing fosmid cloneswere grown in tryptone broth (TB; 11.8 g/l Bacto tryp-
tone, 23.6 g/l yeast extract, 9.4 g/l K2HPO4, 2.2 g/l KH2PO4, 2 g/l glycerol) con-
taining 12.5 mg/ml chloramphenicol, for 16 hr at 37C with shaking at 225 rpm.
When increased fosmid copy number was desired, 13 Replicator induction
solution (Lucigen) was included to activate the medium-copy number origin
of replication (oriV) of the pSmart vector to increase its number to 20–50 copies
per cell.1646 Chemistry & Biology 18, 1640–1648, December 23, 2011 ª2011P. polymyxa PKB1 strains were routinely grown in glucose broth (GB; 10 g/l
glucose, 10 g/l peptone, 2 g/l beef extract, 1 g/l yeast extract, 5 g/l NaCl) or
Brain Heart Infusion (BHI; Difco) at 37C in a tube roller or rotary shaker for
16 hr at 28C. When required, 15 g/l agar was added to GB or BHI, and
when appropriate, chloramphenicol was added to 5 mg/ml.
L. maculans was grown on potato dextrose agar (PDA) at 28C for 3 d to
produce spores for use as an indicator strain for antifungal bioassay.
DNA Isolation, Manipulation, Cloning, and Sequencing
Plasmid isolation and cloning were carried out according to standard methods
(Birnboim and Doly, 1979). A salting-out protocol originally described for the
isolation of genomic DNA from Streptomyces (Kieser et al., 2000) was used
to prepare gDNA from P. polymyxa PKB1. Restriction endonucleases and
other DNA manipulating and cloning products were manufactured by Roche,
New England BioLabs, or Fermentas Life Sciences. All of the oligonucleotide
primers used were prepared by Integrated DNA Technologies. DNA fragments
separated by agarose gel electrophoresis were isolated using QIAquick gel
extraction kits (QIAGEN). Sequencing of DNA was routinely carried out using
the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems).
Screening of Fosmid Library
All fosmid clones from the PKB1 genomic library were patched with sterile
toothpicks on LB agar plates (12 3 12 in) containing ampicillin at 100 mg/ml.
The plates were incubated at 37C for 16 hr and then colonies were transferred
and lysed, and the DNA was fixed to Hybond-N nylon membranes using a
standard colony-lift procedure (Sambrook et al., 1989).
The probes used to screen the fosmid library were prepared based on
the polymyxin gene sequences obtained from Supercos-1 cosmid clones.
Probe 1 was a 1.67 kb EcoRI fragment isolated from an area near the 50 end
of the polymyxin gene cluster fragment in cosmid Col-8. Probe 2 was a
1.11 kb DNA fragment specific to an area just beyond the 30 end of the poly-
myxin gene cluster and generated with primers pSHA09 and pSHA10 using
cosmid Col-15 as a template. Potential polymyxin gene cluster-containing
clones in the fosmid library were identified by hybridization with nonradioac-
tively labeled DNA probes prepared using the DIG High Prime DNA Labeling
and Detection Starter Kit I (Roche Applied Science) according to the manufac-
turer’s instructions.
Generation of Deletion and Disruption Mutants
All P. polymyxamutants were generated using REDIRECT technology, a PCR-
targeting gene disruption system originally developed for use in Streptomyces
(Gust et al., 2003) and adapted for use in Paenibacillus (Li et al., 2007). Disrup-
tionmutants were generated by replacing all (DpmxC,DpmxD, andDpmxC+D)
or part (DpmxE) of the genes with a PCR-amplified ApraRCmRoriT cassette by
taking advantage of the l-red-mediated recombination functions carried on
plasmid pIJ790. Cosmid Col-9 was used as the platform for creation of all of
the mutants. In each case, the mutation was targeted by incorporating
sequences specific for the gene(s) to be deleted onto the 50 ends of the PCR
primers used to amplify the ApraRCmRoriT cassette. PCR reaction mixtures
used to amplify the ApraRCmRoriT cassette contained 50 ng of template
DNA, 50 pmol of each primer, 50 mmol of each dNTP, and 0.5 U of Taq DNA
polymerase in Taq buffer (200 mM Tris-HCl [pH 8.3], 500 mM KCl, 25 mM
MgCl2). PCR reaction mixtures were incubated at 95
C for 3 min, then 10
cycles of 95C for 45 s, 50C for 45 s, and 72C for 2min, followed by 20 cycles
of 95C for 45 s, 55C for 45 s, and 72C for 2 min, with a final elongation at
72C for 5 min.
Oligonucleotide primers used in this study are listed in Supplemental
Experimental Procedures.
Generation of In-Frame Deletion Mutants
In-frame deletion mutants of P. polymyxa, free of the ApraRCmRoriT cassette,
were generated according to Gust et al. (2003) with some modifications. The
Col-9DpmxC+Dmutant cosmid that was used to create theDpmxC+D double
mutant was transformed into E. coli BT340, an E. coli DH5a derivative strain
carrying a plasmid that expresses FLP recombinase. FLP recombinase recog-
nizes the FRT sites flanking the ApraRCmRoriT cassette and catalyzes site-
specific recombination to remove the intervening sequence between the
FRT sites, leaving an 81 bp in-frame ‘‘scar.’’ Once recombination had takenElsevier Ltd All rights reserved
Chemistry & Biology
Variants of Polymyxin Bplace, the temperature-sensitive FLP recombinase plasmid was removed by
growing the cells at 42C. Cosmids isolated from colonies showing apramycin
and chloramphenicol sensitivity (indicating loss of the ApraRCmRoriT cassette)
were screened by restriction endonuclease digestion to confirm that the
recombination had occurred.
Because the CmR genewas the only antibiotic resistancemarker found to be
useful for selecting P. polymyxa PKB1 exconjugants, the newly constructed
Col-9 DpmxC+D-IF cosmid lacked a usable selectable marker. Therefore,
it was subjected to a second round of PCR-targeted gene replacement to
replace the resident kanamycin resistance gene of Supercos-1 with the
ApraRCmRoriT cassette. The ApraRCmR version of Col-9 DpmxC+D-IF was
then conjugated to wild-type P. polymyxa PKB1, and CmR-resistant excon-
jugants, resulting from integration of the ApraRCmR version of Col-9
DpmxC+D-IF into the chromosome through homologous recombination,
were cultivated in the absence of Cm to allow loss of the integrated plasmid
by a second recombination event. Genomic DNA from CmS colonies was
analyzed by PCR to identify those in which a second recombination event
resulted in replacement of the wild-type pmxC and pmxD genes by the
unmarked in-frame deletion.
The authenticity of all mutants was confirmed by PCR analysis of gDNA.
Bioassays for Antibacterial and Antifungal Activity
The wild-type and mutant strains of P. polymyxa PKB1 were grown in GSC
medium (20 g/l glucose, 20 g/l starch, 20 g/l (NH4)2SO4, 10 g/l yeast extract,
2.6 g/l K2HPO4, 0.1 g/l FeSO4$7H2O, 0.5 g/l MgSO4$7H2O, 0.25 g/l NaCl,
9.0 g/l CaCO3) on a rotary shaker for 72 hr at 30
C and 250 rpm, for antibiotic
production. Cultures were harvested by centrifugation, and the culture super-
natants were mixed with methanol to give a final concentration of 20% (v/v)
and held at 4C for 30 min. The methanol-culture supernatant mixtures were
centrifuged at 15,0003 g, and the clarified extracts were analyzed for antibac-
terial activity by agar diffusion bioassay. Molten LB agar inoculated with E. coli
DH5a culture to 0.1% (v/v) was poured into plates, and 100 ml samples were
applied to wells cut with an 8 mm sterilized cork borer. The plates were then
incubated at 37C for 16 hr and the zones of inhibition were measured.
In some cases, the metabolites in culture supernatants were first concen-
trated by adsorption to a Sep-Pak C18 cartridge (Waters) and elution with
methanol before analysis.
Whole-culture supernatants were assayed for antifungal activity because of
the production of fusaricidin by agar diffusion bioassay against L. maculans as
an indicator fungus. PDA plates were spreadwith a spore stock of L.maculans,
wells were punched with a sterile 10 mm borer, and 150 ml amounts of culture
supernatants were added to each well. The plates were incubated at 28C for
3 days and the zones of inhibition were measured.
HPLC Analysis of Culture Supernatants
HPLC analysis was carried out using an Alliance 2695 separation module
controlled by Waters Millenium32 software (version 3.20). Twenty-five micro-
liter samples of clarified methanol extracts were analyzed on a reverse-phase
Bondclone C18 column (8 mm 3 100 mm, 10 mm; Phenomenex) with a mobile
phase consisting of 0.1 M Na2HPO4 (adjusted to pH 3.0 with H3PO4) and
acetonitrile (77:23) at a flow rate of 2.0 ml/min for 25 min with eluent absor-
bance monitored at 212 nm. Alternatively, when eluent was to be assayed
for bioactivity, 100 ml of Sep-Pak-concentrated sample, equivalent to 2 ml of
culture supernatant, was analyzed, and eluent fractions (1 ml) were collected
and assayed for bioactivity against E. coli DH5a by agar diffusion bioassay.
LC-MS Analysis of Culture Supernatants
LC-MS analysis of culture supernatants of wild-type and mutant P. polymyxa
strains was carried out using a single-quadrupole mass spectrometer (Micro-
mass ZMD-2; Waters) controlled by MassLynx software. Samples were
analyzed by injecting 5–10 ml of Sep-Pak-concentrated culture supernatant
onto a reverse-phase XTerraMSC18 column (2.1mm3 150mm, 5 mm;Waters)
with a mobile phase consisting of 0.1% formic acid (adjusted to pH 3.0 with
ammonium hydroxide) and acetonitrile (77:23) at a flow rate of 0.2 ml/min for
20 min. The column was kept at a temperature of 25C and eluent absorbance
wasmonitored at 212 nm. Mass spectrometric data were acquired for the total
ion current of the samples ionized over time with electrospray ionization oper-
ated in a positive ion mode. The other MS parameters were source tempera-Chemistry & Biology 18, 1640–164ture 150C, desolvation temperature 300C, cone voltage 15V, and nitrogen
gas flow 15 l/min. Full mass spectra were acquired over a mass range of
m/z 450–1,400 with a scan time of 1.0 s and interscan time of 0.1 s.
Material representing each bioactive peak was purified for subsequent
analysis by semipreparative HPLC. One hundred microliter samples of Sep-
Pak-concentrated culture supernatant were repeatedly injected onto the
Bondclone C18 column and eluted using a mobile phase of 0.1% formic acid
(adjusted to pH 3.0 with ammonium hydroxide) and acetonitrile (77:23) at
a flow rate of 2 ml/min. Bioactive fractions were pooled and concentrated on
a rotary evaporator.
High-Resolution MS and MS/MS Sequencing
After HPLC purification, the high-resolution matrix-assisted laser desorption
ionization-Fourier transform ion cyclotron resonance-mass spectrometry
(MALDI-FTICR-MS) spectrum of the peptides (3 and 4) was obtained using
a Bruker 9.4T Apex-Qe FTICR (Bruker Daltonics). For D-DAB3-polymyxin
B1 (3), an elemental composition of C56H99N16O13 for the (M+H)
+ ion was
obtained with a mass accuracy of 0.63 ppm. For D-DAB3-polymyxin B2 (4),
an elemental composition of C55H97N16O13 for the (M+H)
+ ion was obtained
with a mass accuracy of 0.81 ppm. The proposed peptide sequences were
confirmed by tandem MALDI-MS/MS analysis (Figure 4; Figure S1; Table
S1). To do this, HPLC-purified and concentrated peptide solutions were
directly spotted onto a Bruker Daltonics MTP AnchorChip 800/384 target
and air dried. Then 0.42 ml of a-cyano-4-hydroxycinnamic acid matrix solution
was spotted on top and air dried. The matrix solution was prepared as follows.
A 36 ml aliquot of a saturated matrix solution prepared in 0.1% TFA in 90:10
ACN:H2O was diluted to a final volume of 800 ml using 0.1% TFA in 85:15
ACN:H2O, containing 1 mM ammonium phosphate. Mass spectra were
obtained in the positive reflectron mode of ionization using a Bruker Daltonics
ultrafleXtreme MALDI TOF/TOF mass spectrometer. The MS/MS spectra
were obtained manually with collision-induced dissociation gas turned off.
DataAnalysis, BioTools, and Sequence Editor software packages provided
by the manufacturer were used for analysis of the mass spectra.
MS/MS sequencing of D-DAB polymyxin B1 (3) and B2 (4) is made more
complex by the cyclic nature of the peptides, as the C terminus of each peptide
is connected to the amino side chain of residue 4 by an amide bond. This
means that the formation of smaller ions is often the product of two fragmen-
tations, one to open the ring and a second to shorten the resulting linear
peptide. When the peptide fragments in the spectrometer and the ring is
opened, either the bond between the C terminus and the side chain of residue
4 or the backbone amide bond between residues 4 and 5 breaks. When the
side chain to C-terminal bond breaks, the resulting linear peptide follows the
sequence residues 1–10. However, if the backbone bond between residues
4 and 5 breaks, the resulting linear peptide has the sequence 1, 2, 3, 4, 10,
9, 8, 7, 6, 5. Using both sets of linear fragments along with larger fragments
containing an intact ring, the sequences of 3 and 4 were confirmed.
Hydrolysis and Derivatization of Polymyxin Samples
Each peptide sample (1 mg) was heated to 110C in a sealed tube in 6 M HCl
(3 ml) for 18 hr. The solution was allowed to cool to room temperature and the
solvent was removed in vacuo. Acetyl chloride (1.5 ml) was added dropwise to
isopropyl alcohol (5 ml) at 0C. This solution was added to the peptide residue,
and the mixture was heated to 110C in a sealed tube for 45 min. The solution
was allowed to cool and the solvent was removed in vacuo. A solution of pen-
tafluoropropionic anhydride (1 ml) in dichloromethane (3 ml) was added to the
peptide residue, and the mixture was heated to 110C in a sealed tube for
15 min. The mixture was allowed to cool to room temperature and then the
solvent was evaporated under a stream of argon. The resulting residue was
dissolved in dichloromethane (1 ml) and transferred to a vial for storage. Deriv-
atization of standard amino acids was carried out in the above manner, except
the first step used 0.2 M HCl as solvent and was only heated for 15 min.
Chiral GC/MS Analysis of Polymyxin Samples
The hydrolyzed and derivatized samples of 3 and 4 were analyzed using chiral
GC/MS. All samples were analyzed using a Varian 25m3 0.22mm fused silica
wall-coated open tubular Chirasil-L-Val (0.12 mm) column on an Agilent Tech-
nologies 7890 GC with 5975C MSD and 7683B series injector. Each sample
was introduced into the machine dissolved in dichloromethane via a pulsed8, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1647
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180C by 3C/min.
Each peptide was analyzed independently, and then the two peptides were
mixed together and analyzed (Figure 6; Figure S2). It was found that 3 and 4
contained the same amino acids. The identity of each amino acid in the peptide
was confirmed by sequential addition of derivatized standard amino acids.
This confirmed that the amino acids present were indeed L-threonine,
L-leucine, D-phenylalanine, L-2,4-diaminobutyric acid, and D-2,4-diaminobu-
tyric acid. The integration supports that the ratio of L:D diaminobutyric acid
is 5:1.
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